Eton Pharmaceuticals Announces Commercial Availability of Ultra-Rare Disease Product Nitisinone Capsules
02 févr. 2024 06h50 HE
|
Eton Pharmaceuticals
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Current Nitisinone market is estimated to exceed $50 million annually ---- Product is now...
Eton Pharmaceuticals Reports Third Quarter 2023 Financial Results
09 nov. 2023 16h01 HE
|
Eton Pharmaceuticals
Product sales and royalty revenue of $7.0 million up 118% from Q3 2022, representing the eleventh straight quarter of sequential product sales and royalty revenue growthGenerated $0.9 million in...
Eton Pharmaceuticals to Report Third Quarter 2023 Financial Results on Thursday, November 9, 2023
30 oct. 2023 06h50 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing, acquiring, and commercializing products to...
Eton Pharmaceuticals Announces Acquisition of FDA-Approved Ultra-Rare Disease Product Nitisinone
04 oct. 2023 06h50 HE
|
Eton Pharmaceuticals
-- Expect Q1 2024 product launch ---- Nitisinone market estimated to be more than $50 million annually ---- Eton will offer Eton Cares support program to all patients -- DEER PARK, Ill., Oct. 04,...
Eton Pharmaceuticals to Present at the H.C. Wainwright 25th Annual Global Investment Conference
23 août 2023 06h50 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 23, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports Second Quarter 2023 Financial Results
10 août 2023 16h01 HE
|
Eton Pharmaceuticals
Total Q2 revenue of $12.0 million and net income of $4.6 millionProduct sales and royalty revenue of $6.5 million up 175% from Q2 2022 and 22% from Q1 2023$21.6 million of cash on handLaunched Betaine...
Eton Pharmaceuticals to Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023
01 août 2023 16h05 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc. (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Receives Complete Response Letter (CRL) for Dehydrated Alcohol Injection
28 juin 2023 06h50 HE
|
Eton Pharmaceuticals
DEER PARK, Ill., June 28, 2023 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare...
Eton Pharmaceuticals Reports First Quarter 2023 Financial Results
11 mai 2023 16h01 HE
|
Eton Pharmaceuticals
Product sales and royalty revenue of $5.3 million up 144% from Q1 2022 and 52% from Q4 2022Launched Betaine AnhydrousManagement to hold conference call today at 4:30pm ET DEER PARK, Ill., May 11,...
Eton Pharmaceuticals Announces Commercial Availability of Betaine Anhydrous for Oral Solution, a Generic Version of Cystadane® (betaine anhydrous for oral solution)
10 mai 2023 06h50 HE
|
Eton Pharmaceuticals
-- Eton Cares patient support program offers $0 co-pay to eligible, commercially insured patients* ---- Product is now available exclusively through Optime Care -- DEER PARK, Ill., May 10, 2023 ...